<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7409942\results\search\disease\results.xml">
  <result pre="Biosciences0025-55641879-3134Elsevier Inc. pmcid: 7409942S0025-5564(20)30105-X doi: 10.1016/j.mbs.2020.108438108438 : Article Modeling the" exact="viral" post="dynamics of SARS-CoV-2 infection WangSunpengaPanYangbcdWangQuanyibcMiaoHongyueBrownAshley N.fRongLibingâ�Ž[a], [b], [c], [d],"/>
  <result pre="doi: 10.1016/j.mbs.2020.108438108438 : Article Modeling the viral dynamics of SARS-CoV-2" exact="infection" post="WangSunpengaPanYangbcdWangQuanyibcMiaoHongyueBrownAshley N.fRongLibingâ�Ž[a], [b], [c], [d], [e], [f], [g], â�ŽCorresponding"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="long as the COVID-19 resource centre remains active. Abstract Coronavirus" exact="disease" post="2019 (COVID-19), an infectious disease caused by the infection"/>
  <result pre="resource centre remains active. Abstract Coronavirus disease 2019 (COVID-19), an" exact="infectious disease" post="caused by the infection of severe acute respiratory syndrome"/>
  <result pre="centre remains active. Abstract Coronavirus disease 2019 (COVID-19), an infectious" exact="disease" post="caused by the infection of severe acute respiratory syndrome"/>
  <result pre="Coronavirus disease 2019 (COVID-19), an infectious disease caused by the" exact="infection" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is"/>
  <result pre="(COVID-19), an infectious disease caused by the infection of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading and causing"/>
  <result pre="an infectious disease caused by the infection of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), is spreading and causing the"/>
  <result pre="infectious disease caused by the infection of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), is spreading and causing the global"/>
  <result pre="(SARS-CoV-2), is spreading and causing the global coronavirus pandemic. The" exact="viral" post="dynamics of SARS-CoV-2 infection have not been quantitatively investigated."/>
  <result pre="causing the global coronavirus pandemic. The viral dynamics of SARS-CoV-2" exact="infection" post="have not been quantitatively investigated. In this paper, we"/>
  <result pre="use mathematical models to study the pathogenic features of SARS-CoV-2" exact="infection" post="by examining the interaction between the virus, cells and"/>
  <result pre="immune responses. Models are fit to the data of SARS-CoV-2" exact="infection" post="in patients and non-human primates. Data fitting and numerical"/>
  <result pre="and non-human primates. Data fitting and numerical simulation show that" exact="viral" post="dynamics of SARS-CoV-2 infection have a few distinct stages."/>
  <result pre="fitting and numerical simulation show that viral dynamics of SARS-CoV-2" exact="infection" post="have a few distinct stages. In the initial stage,"/>
  <result pre="infection have a few distinct stages. In the initial stage," exact="viral" post="load increases rapidly and reaches the peak, followed by"/>
  <result pre="by a plateau phase possibly generated by lymphocytes as a" exact="secondary" post="target of infection. In the last stage, viral load"/>
  <result pre="as a secondary target of infection. In the last stage," exact="viral" post="load declines due to the emergence of adaptive immune"/>
  <result pre="initiation of seroconversion is late or slow, the model predicts" exact="viral" post="rebound and prolonged viral persistence, consistent with the observation"/>
  <result pre="late or slow, the model predicts viral rebound and prolonged" exact="viral" post="persistence, consistent with the observation in non-human primates. Using"/>
  <result pre="with interferon are effective in reducing the duration of the" exact="viral" post="plateau phase and diminishing the time to recovery. These"/>
  <result pre="time to recovery. These results provide insights for understanding the" exact="infection" post="dynamics and might help develop treatment strategies against COVID-19."/>
  <result pre="are developed to study SARS-CoV-2 infection. â€¢Models are fit to" exact="viral" post="load data of patients and non-human primates. â€¢Viral dynamics"/>
  <result pre="data of patients and non-human primates. â€¢Viral dynamics of SARS-CoV-2" exact="infection" post="has a few distinct stages. â€¢Model explains viral rebound"/>
  <result pre="of SARS-CoV-2 infection has a few distinct stages. â€¢Model explains" exact="viral" post="rebound and prolonged viral persistence. â€¢Implication for treatment strategies"/>
  <result pre="a few distinct stages. â€¢Model explains viral rebound and prolonged" exact="viral" post="persistence. â€¢Implication for treatment strategies is discussed. 1 Introduction"/>
  <result pre="is discussed. 1 Introduction In late December 2019, highly contagious" exact="pneumonia" post="of unknown etiology was first reported in Wuhan, ChinaÂ"/>
  <result pre="strain of coronavirus was isolated from patients and named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) by the World Health"/>
  <result pre="of coronavirus was isolated from patients and named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) by the World Health OrganizationÂ"/>
  <result pre="coronavirus was isolated from patients and named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) by the World Health OrganizationÂ [10]."/>
  <result pre="(SARS-CoV-2) by the World Health OrganizationÂ [10]. Since then, SARS-CoV-2" exact="infection" post="has been detected in about 190 countries and caused"/>
  <result pre="worldwideÂ [9], [11], [12], [13], [14], [15]. Infected individuals develop" exact="acute" post="respiratory distress syndrome (ARDS) characterized by lymphocytopenia and hyperactive"/>
  <result pre="[9], [11], [12], [13], [14], [15]. Infected individuals develop acute" exact="respiratory" post="distress syndrome (ARDS) characterized by lymphocytopenia and hyperactive inflammatory"/>
  <result pre="[12], [13], [14], [15]. Infected individuals develop acute respiratory distress" exact="syndrome" post="(ARDS) characterized by lymphocytopenia and hyperactive inflammatory response, which"/>
  <result pre="[16]. High-throughput sequencing demonstrates that SARS-CoV-2 highly resembles the severe" exact="acute" post="respiratory syndrome (SARS-CoV) and the Middle East respiratory syndrome"/>
  <result pre="High-throughput sequencing demonstrates that SARS-CoV-2 highly resembles the severe acute" exact="respiratory" post="syndrome (SARS-CoV) and the Middle East respiratory syndrome (MERS-CoV),"/>
  <result pre="sequencing demonstrates that SARS-CoV-2 highly resembles the severe acute respiratory" exact="syndrome" post="(SARS-CoV) and the Middle East respiratory syndrome (MERS-CoV), both"/>
  <result pre="the severe acute respiratory syndrome (SARS-CoV) and the Middle East" exact="respiratory" post="syndrome (MERS-CoV), both classified as beta coronaviruses identified in"/>
  <result pre="severe acute respiratory syndrome (SARS-CoV) and the Middle East respiratory" exact="syndrome" post="(MERS-CoV), both classified as beta coronaviruses identified in batsÂ"/>
  <result pre="by SARS-CoV [23], [24], [25], [26], [27], to infect humans." exact="Lymphocytopenia" post="is an indicator of the severity and mortality in"/>
  <result pre="indicator of the severity and mortality in patients with coronavirus" exact="disease" post="of 2019 (COVI-19)Â [4], [28], [29], [30], [31], [32],"/>
  <result pre="have significantly low lymphocyte count, possibly due to the direct" exact="infection" post="by coronavirus, leading to cytoplasmic damage and destruction of"/>
  <result pre="of lymphocytes to the lung and result in the consequent" exact="pulmonary" post="injuryÂ [36]. These findings suggest that SARS-CoV-2 might rely"/>
  <result pre="develop a vicious cycle to drive lymphocytes to lung for" exact="infection" post="to maintain the viral replication and transmissibility. Currently, there"/>
  <result pre="to drive lymphocytes to lung for infection to maintain the" exact="viral" post="replication and transmissibility. Currently, there are no approved antiviral"/>
  <result pre="approved antiviral drugs for SARS-CoV-2 infection. Many patients were given" exact="symptomatic" post="management such as empirical broad-spectrum antibiotics or anti-influenza therapiesÂ"/>
  <result pre="anti-influenza therapiesÂ [38]. Mechanical ventilations were used in patients with" exact="respiratory" post="failure. The mortality of COVID-19 patients is primarily caused"/>
  <result pre="recovered from COVID-19 still tested positive or even had long-term" exact="viral" post="sheddingÂ [29], [42]. The mechanisms underlying these pathogenic features"/>
  <result pre="[43], [44], [45], [46], [47], [48], [49]. However, the within-host" exact="viral" post="dynamics of SARS-CoV-2 infection have not been quantitatively investigated."/>
  <result pre="[47], [48], [49]. However, the within-host viral dynamics of SARS-CoV-2" exact="infection" post="have not been quantitatively investigated. Here we use mathematical"/>
  <result pre="use mathematical models to study the pathogenic characteristics of SARS-CoV-2" exact="infection" post="by examining the interaction between viral replication and the"/>
  <result pre="pathogenic characteristics of SARS-CoV-2 infection by examining the interaction between" exact="viral" post="replication and the host immune responses. We fit models"/>
  <result pre="some potential therapies against COVID-19. Combination of antiviral drugs and" exact="type I" post="interferon (IFN) may control the SARS-CoV-2 replication. This is"/>
  <result pre="findings may provide new insights into the pathogenesis of SARS-CoV-2" exact="infection" post="and development of new treatment strategies. 2 Methods 2.1"/>
  <result pre="treatment strategies. 2 Methods 2.1 Patient and experiment data The" exact="viral" post="load data in COVID-19 patients with and without treatment"/>
  <result pre="from Germany, South Korea and China. We also studied the" exact="viral" post="load data from a SARS-CoV-2 infected adult rhesus macaque"/>
  <result pre="also studied the viral load data from a SARS-CoV-2 infected" exact="adult" post="rhesus macaque in the US. The viral load data"/>
  <result pre="a SARS-CoV-2 infected adult rhesus macaque in the US. The" exact="viral" post="load data of eight patients from Germany were from"/>
  <result pre="from a larger cohort of COVID-19 cases in MunichÂ [54]." exact="Viral" post="RNA levels of all patients were measured every day"/>
  <result pre="due to the lack of enough measurements in another. The" exact="viral" post="load data from South Korea were from a 35-year-old"/>
  <result pre="She was the first case reported in South Korea. The" exact="viral" post="load was also measured with RT-PCR every day after"/>
  <result pre="with lopinavir/ritonavir on day 5 since symptomâ€™s onset. The rectal" exact="viral" post="load data from a rhesus macaque having prolonged viral"/>
  <result pre="rectal viral load data from a rhesus macaque having prolonged" exact="viral" post="shedding were collected by RT-PCR every day from its"/>
  <result pre="its rectal swab samples after inoculationÂ [52]. 2.2 A basic" exact="viral" post="dynamic model We use three models, with increasing complexity,"/>
  <result pre="We use three models, with increasing complexity, to study the" exact="viral" post="dynamics of SARS-CoV-2 infection. The first is a very"/>
  <result pre="in the basic model and the third one includes a" exact="secondary" post="target cell population of SARS-CoV-2 infection. The basic model"/>
  <result pre="p I âˆ’ c V The exact target of SARS-CoV-2" exact="infection" post="is not fully clear. Based on the findings from"/>
  <result pre="results from SARS-CoV-2 infectionÂ [36], [57], [58], SARS-CoV-2 can infect" exact="type II" post="pneumocytesÂ [59]. Target cells (T) are assumed to be"/>
  <result pre="The virus is cleared at a constant rate c. SARS-CoV-2" exact="infection" post="can lead to the diffuse alveolar damage (DAD)Â [60]."/>
  <result pre="a constant rate c. SARS-CoV-2 infection can lead to the" exact="diffuse" post="alveolar damage (DAD)Â [60]. DAD usually has three phases:"/>
  <result pre="diffuse alveolar damage (DAD)Â [60]. DAD usually has three phases:" exact="exudative" post="phase, proliferative phase and fibrotic phaseÂ [61]. In the"/>
  <result pre="exudative phase, proliferative phase and fibrotic phaseÂ [61]. In the" exact="exudative" post="phase, immune cells are recruited to the lung, causing"/>
  <result pre="exchange. The proliferative phase is characterized by regeneration of alveolar" exact="type II" post="epithelial cells or pneumocytes Â [62]. When replicating, type"/>
  <result pre="proliferative phase is characterized by regeneration of alveolar type II" exact="epithelial" post="cells or pneumocytes Â [62]. When replicating, type II"/>
  <result pre="type II epithelial cells or pneumocytes Â [62]. When replicating," exact="type II" post="epithelial cells transport fluid out of the airspace. SARS-CoV-2"/>
  <result pre="epithelial cells or pneumocytes Â [62]. When replicating, type II" exact="epithelial" post="cells transport fluid out of the airspace. SARS-CoV-2 infects"/>
  <result pre="infects pneumocytes and induces hyperactive inflammation that greatly enhances the" exact="exudative" post="reaction. Thus, pneumocytes may experience a significant delay in"/>
  <result pre="could be at a minimum level. Therefore, when studying the" exact="viral" post="dynamics during the early stage of infection, we do"/>
  <result pre="I 2 âˆ’ c V 2.4 The model with a" exact="secondary" post="target of infection Previous studiesÂ [30], [31], [33] detected"/>
  <result pre="c V 2.4 The model with a secondary target of" exact="infection" post="Previous studiesÂ [30], [31], [33] detected a large number"/>
  <result pre="Previous studiesÂ [30], [31], [33] detected a large number of" exact="viral" post="particles within lymphocytes of SARS-CoV and MERS-CoV patients. A"/>
  <result pre="SARS-CoV and MERS-CoV patients. A new study also found the" exact="infection" post="of T lymphocytes by SARS-CoV-2Â [35]. We include lymphocytes"/>
  <result pre="T lymphocytes by SARS-CoV-2Â [35]. We include lymphocytes as a" exact="secondary" post="target cell population in the basic model. d T"/>
  <result pre="rate Î» to represent the recruitment of lymphocytes to the" exact="infection" post="site due to the lung inflammatory response. This was"/>
  <result pre="the lung inflammatory response. This was also assumed in the" exact="viral" post="dynamic models that studied HIV primary infection and influenza"/>
  <result pre="also assumed in the viral dynamic models that studied HIV" exact="primary" post="infection and influenza virus infectionÂ [55], [68]. To minimize"/>
  <result pre="assumed in the viral dynamic models that studied HIV primary" exact="infection" post="and influenza virus infectionÂ [55], [68]. To minimize the"/>
  <result pre="NK cells can recognize and kill stressed cells in the" exact="absence of" post="antibodiesÂ [70], [71], [72], [73]. Because of the lack"/>
  <result pre="by Pawelek etÂ al. to study the control of influenza" exact="virus infection" post="by the adaptive immune responseÂ [68], it will introduce"/>
  <result pre="Pawelek etÂ al. to study the control of influenza virus" exact="infection" post="by the adaptive immune responseÂ [68], it will introduce"/>
  <result pre="estimation from data fitting. Because we aim to model the" exact="viral" post="elimination in the end of infection, the exponentially increasing"/>
  <result pre="this purpose. Fig. 1 Schematic diagram of model (3). The" exact="secondary" post="target cells ( T 2 ) are recruited to"/>
  <result pre="target cell populations are infected by SARS-CoV-2 with the same" exact="infection" post="rate Î². Infected cells can be removed by the"/>
  <result pre="â€&quot; I 2 Productively infected cells â€&quot; â€&quot; T 1" exact="Primary" post="target cells/pneumocytes â€&quot; â€&quot; T 2 Secondary target cells/lymphocytes"/>
  <result pre="â€&quot; T 1 Primary target cells/pneumocytes â€&quot; â€&quot; T 2" exact="Secondary" post="target cells/lymphocytes â€&quot; â€&quot; V Virus â€&quot; â€&quot; Î²"/>
  <result pre="Secondary target cells/lymphocytes â€&quot; â€&quot; V Virus â€&quot; â€&quot; Î²" exact="Viral" post="infection rate Fitted Î´ I Base death rate of"/>
  <result pre="target cells/lymphocytes â€&quot; â€&quot; V Virus â€&quot; â€&quot; Î² Viral" exact="infection" post="rate Fitted Î´ I Base death rate of productively"/>
  <result pre="productive stage Fitted c Clearance rate of virus Fitted p" exact="Viral" post="production rate Fitted Ï‰ Killing rate by innate immune"/>
  <result pre="innate immune response Fitted Î» Recruitment of lymphocytes to the" exact="infection" post="site 104 dayâˆ’1 [69] Ïƒ Parameter in the killing"/>
  <result pre="Fig. 2 Best fits of model (3) to the LRT" exact="viral" post="load data in patients from GermanyÂ [14]. The patients"/>
  <result pre="Fig. 3 Best fits of model (3) to the URT" exact="viral" post="load data in patients from GermanyÂ [14]. The other"/>
  <result pre="( Î») to be 104 cells mlâˆ’1 dayâˆ’1Â [69]. The" exact="total" post="number of alveoli cells within a human is about"/>
  <result pre="within a human is about 6 Ã—108 cellsÂ [74], [75]." exact="Type II" post="pneumocytes constitute 60% of the total alveolar cellsÂ [76]"/>
  <result pre="cellsÂ [74], [75]. Type II pneumocytes constitute 60% of the" exact="total" post="alveolar cellsÂ [76] and the volume of lung is"/>
  <result pre="6 Ã—104 cells/ml. The initial value of lymphocytes at the" exact="infection" post="site is 0. There are no infected cells at"/>
  <result pre="the initial time. We fit models to the data of" exact="viral" post="load extracted from sputum/saliva. Because much of the early"/>
  <result pre="viral load extracted from sputum/saliva. Because much of the early" exact="infection" post="occurs in the lung and only a small proportion"/>
  <result pre="after infection, we assume V(0) to be an effective initial" exact="viral" post="concentration and choose the value of V(0) from 10âˆ’6"/>
  <result pre="of the parameters by fitting models to the data of" exact="viral" post="load. All the variables and parameters are summarized in"/>
  <result pre="i 2 n where V( t i ) represents the" exact="viral" post="load level at time t i predicted by the"/>
  <result pre="is performed using the R programming language. 3 Results 3.1" exact="Viral" post="dynamics of SARS-CoV-2 infection We fit each of the"/>
  <result pre="R programming language. 3 Results 3.1 Viral dynamics of SARS-CoV-2" exact="infection" post="We fit each of the three models Eqs. ((1)â€&quot;(3))"/>
  <result pre="fit each of the three models Eqs. ((1)â€&quot;(3)) to the" exact="viral" post="load data of SARS-CoV-2 infection in patients from Germany"/>
  <result pre="models Eqs. ((1)â€&quot;(3)) to the viral load data of SARS-CoV-2" exact="infection" post="in patients from Germany and ChinaÂ [14], [51]. The"/>
  <result pre="ChinaÂ [14], [51]. The best fits to the data from" exact="lower" post="respiratory tract (LRT) and upper respiratory tract (URT) using"/>
  <result pre="[14], [51]. The best fits to the data from lower" exact="respiratory" post="tract (LRT) and upper respiratory tract (URT) using model"/>
  <result pre="fits to the data from lower respiratory tract (LRT) and" exact="upper" post="respiratory tract (URT) using model (3) are shown in"/>
  <result pre="to the data from lower respiratory tract (LRT) and upper" exact="respiratory" post="tract (URT) using model (3) are shown in Fig."/>
  <result pre="(1) and (2) is that these models show a single-phase" exact="viral" post="decline after the peak. This is not consistent with"/>
  <result pre="decline after the peak. This is not consistent with the" exact="viral" post="plateau or even a second peak observed in some"/>
  <result pre="is complicated. Using a constant rate fails to explain the" exact="viral" post="plateau and subsequent decline of the viral load observed"/>
  <result pre="to explain the viral plateau and subsequent decline of the" exact="viral" post="load observed in patientsÂ [14], [51]. Numerical simulations of"/>
  <result pre="[14], [51]. Numerical simulations of model (3) show that the" exact="viral" post="dynamics of SARS-CoV-2 infection can exhibit a few distinct"/>
  <result pre="of model (3) show that the viral dynamics of SARS-CoV-2" exact="infection" post="can exhibit a few distinct phases (Fig.Â 5A). During"/>
  <result pre="few distinct phases (Fig.Â 5A). During the first stage, the" exact="primary" post="target cells are infected and consumed rapidly. The viral"/>
  <result pre="the primary target cells are infected and consumed rapidly. The" exact="viral" post="load experiences a substantial increase to the peak level."/>
  <result pre="of ARDS are observed around this timeÂ [14]. Following the" exact="viral" post="peak, the viral load declines slightly and enters a"/>
  <result pre="observed around this timeÂ [14]. Following the viral peak, the" exact="viral" post="load declines slightly and enters a plateau phase in"/>
  <result pre="declines slightly and enters a plateau phase in which the" exact="viral" post="load remains approximately unchanged or declines slowly. In our"/>
  <result pre="our model, the source of this plateau phase is the" exact="infection" post="of lymphocytes as a secondary target. Without the infection"/>
  <result pre="this plateau phase is the infection of lymphocytes as a" exact="secondary" post="target. Without the infection of lymphocytes, SARS-CoV-2 would continue"/>
  <result pre="the infection of lymphocytes as a secondary target. Without the" exact="infection" post="of lymphocytes, SARS-CoV-2 would continue to infect and deplete"/>
  <result pre="would continue to infect and deplete pneumocytes. As a consequence," exact="viral" post="load would decline quickly and the infected individual would"/>
  <result pre="the infected individual would lose the transmissibility (Fig.Â 5A). After" exact="viral" post="load persists for a period of time (e.g.Â a"/>
  <result pre="onset of ARDS in COVID-19 patientsÂ [14]. During this stage," exact="viral" post="load declines rapidly to an undetectable level. This also"/>
  <result pre="oxygen treatment, mechanical ventilation, corticosteroids and antibiotics to maintain the" exact="respiratory" post="function and ease the inflammatory response. This provides time"/>
  <result pre="[40]. In Fig.Â 5B, we simulate the dynamics of the" exact="viral" post="load with adaptive immune response activated at different time."/>
  <result pre="later the adaptive immune response takes place, the longer the" exact="viral" post="load persists. Many senior patients die from COVID-19 because"/>
  <result pre="[80]. The best fits with the model show that the" exact="viral infection" post="rate is significantly higher in URT, but the viral"/>
  <result pre="The best fits with the model show that the viral" exact="infection" post="rate is significantly higher in URT, but the viral"/>
  <result pre="viral infection rate is significantly higher in URT, but the" exact="viral" post="production rate and the immune response (described by Ï‰"/>
  <result pre="is transmitted from one host to another via exhaled air," exact="respiratory" post="droplets or fine-particle aerosolsÂ [81]. The primary infection of"/>
  <result pre="via exhaled air, respiratory droplets or fine-particle aerosolsÂ [81]. The" exact="primary" post="infection of SARS-CoV-2 occurs in the URT while the"/>
  <result pre="exhaled air, respiratory droplets or fine-particle aerosolsÂ [81]. The primary" exact="infection" post="of SARS-CoV-2 occurs in the URT while the systematic"/>
  <result pre="to prevent transmission of SARS-CoV-2 from infected individualsÂ [82]. 3.2" exact="Viral" post="rebound and persistence Some patients still tested positive after"/>
  <result pre="after recovering from COVID-19Â [42], [83]. The biological process underlying" exact="viral" post="rebound is unknown. Our simulation in Fig.Â 6A shows"/>
  <result pre="slowly as the adaptive immune response emerges, then a second" exact="viral" post="peak is predicted because the adaptive immune response is"/>
  <result pre="the adaptive immune response is not sufficient to control the" exact="viral" post="replication. Thus, viral rebound that lasts for a period"/>
  <result pre="response is not sufficient to control the viral replication. Thus," exact="viral" post="rebound that lasts for a period of time can"/>
  <result pre="As Î´ (t) increases to above a certain level, the" exact="viral" post="load will decline again and eventually be eliminated (Fig.Â"/>
  <result pre="timing of the emergence of adaptive immune response also affects" exact="viral" post="rebound and persistence. If the adaptive immune system is"/>
  <result pre="If the adaptive immune system is activated later, then the" exact="viral" post="load can persist at a higher level for a"/>
  <result pre="primate with the lowest and latest antibody response had prolonged" exact="viral" post="shedding from the intestinal tractÂ [52]. We also fit"/>
  <result pre="tractÂ [52]. We also fit our model to the rectal" exact="viral" post="load data of this animal and the fit is"/>
  <result pre="for infected individuals with compromised or delayed immune responses, the" exact="viral" post="load will rebound following the first peak and even"/>
  <result pre="of model (3) to the URT (A) and LRT (B)" exact="viral" post="load data in a patient from ChinaÂ [51]. The"/>
  <result pre="remdesivir were suggested to be remedy that might inhibit SARS-CoV-2" exact="viral" post="replicationÂ [85], [86]. Lopinavir/ritonavir is a combination of protease"/>
  <result pre="[87], while remdesivir was developed to treat Ebola and Marburg" exact="virus infection," post="acting as an analog of adenosine nucleotide to confuse"/>
  <result pre="infection, acting as an analog of adenosine nucleotide to confuse" exact="viral" post="RNA polymerase and evade proofreading by viral exoribonuclease (ExoN)Â"/>
  <result pre="nucleotide to confuse viral RNA polymerase and evade proofreading by" exact="viral" post="exoribonuclease (ExoN)Â [88]. We assume that they reduce the"/>
  <result pre="the prediction of model (3) with the LRT and URT" exact="viral" post="load data of a patient in South Korea who"/>
  <result pre="that the efficacy of lopinavir/ritonavir is 60% effective in reducing" exact="viral" post="replication in the LRT while it does not have"/>
  <result pre="find that a higher efficacy of antiviral drugs only makes" exact="viral" post="load decline slightly faster. However, early treatment can significantly"/>
  <result pre="to recovery. SARS-CoV-2 is shown to be more sensitive to" exact="type I" post="interferon (IFN) than SARS-CoV due to the absence of"/>
  <result pre="to type I interferon (IFN) than SARS-CoV due to the" exact="absence of" post="two important IFN antagonistsÂ [53]. We examine the impact"/>
  <result pre="killing by the innate immune response can largely suppress the" exact="viral" post="replication (compare Fig.Â 8A,C). Under IFN treatment, the viral"/>
  <result pre="the viral replication (compare Fig.Â 8A,C). Under IFN treatment, the" exact="viral" post="load could be significantly reduced with 60% drug efficacy"/>
  <result pre="drugs might be promising against novel coronavirus infection. The severe" exact="acute" post="respiratory syndrome induced by SARS-CoV-2 infection is characterized by"/>
  <result pre="might be promising against novel coronavirus infection. The severe acute" exact="respiratory" post="syndrome induced by SARS-CoV-2 infection is characterized by over-exuberant"/>
  <result pre="be promising against novel coronavirus infection. The severe acute respiratory" exact="syndrome" post="induced by SARS-CoV-2 infection is characterized by over-exuberant inflammatory"/>
  <result pre="coronavirus infection. The severe acute respiratory syndrome induced by SARS-CoV-2" exact="infection" post="is characterized by over-exuberant inflammatory response. Baricitinib, fedratinib and"/>
  <result pre="(Fig.Â 8D). The result implies that anti-inflammation drugs can accelerate" exact="viral" post="decline because of the limited availability of the secondary"/>
  <result pre="that anti-inflammation drugs can accelerate viral decline because of the" exact="limited" post="availability of the secondary target of infection. 4 Discussion"/>
  <result pre="accelerate viral decline because of the limited availability of the" exact="secondary" post="target of infection. 4 Discussion Within-host dynamics of SARS-CoV-2"/>
  <result pre="secondary target of infection. 4 Discussion Within-host dynamics of SARS-CoV-2" exact="infection" post="have not been quantitatively investigated. We developed mathematical models"/>
  <result pre="been quantitatively investigated. We developed mathematical models to study the" exact="viral" post="dynamics and compared modeling prediction with the viral load"/>
  <result pre="study the viral dynamics and compared modeling prediction with the" exact="viral" post="load data in COVID-19 patients and non-human primates from"/>
  <result pre="very high transmission capacity is likely to come from a" exact="viral" post="plateau phase after the peak, which provides a sustainable"/>
  <result pre="phase after the peak, which provides a sustainable source of" exact="infectious" post="viruses. The duration of the plateau stage is determined"/>
  <result pre="model shows that the current best possible control of SARS-CoV-2" exact="infection" post="might be the adaptive immune response of the infected"/>
  <result pre="of adaptive immunity. Thirdly, we explained the scenario of prolonged" exact="viral" post="shedding and viral rebound. They originate from the oscillation"/>
  <result pre="Thirdly, we explained the scenario of prolonged viral shedding and" exact="viral" post="rebound. They originate from the oscillation caused by interplays"/>
  <result pre="rebound. They originate from the oscillation caused by interplays between" exact="viral" post="replication and the adaptive immune response. If seroconversion emerges"/>
  <result pre="the adaptive immune response. If seroconversion emerges late, then prolonged" exact="viral" post="persistence is generated. As the adaptive immune response is"/>
  <result pre="Comparison of the prediction by the three models and the" exact="viral" post="load data suggests that SARS-CoV-2 infection might have a"/>
  <result pre="three models and the viral load data suggests that SARS-CoV-2" exact="infection" post="might have a secondary target. Without the second target"/>
  <result pre="viral load data suggests that SARS-CoV-2 infection might have a" exact="secondary" post="target. Without the second target cell population, the model"/>
  <result pre="the second target cell population, the model shows a single-phase" exact="viral" post="load decline after the peak, which does not agree"/>
  <result pre="does not agree with the data in many patients. The" exact="secondary" post="target of SARS-CoV-2 infection might be lymphocytes. Lymphocytopenia is"/>
  <result pre="the data in many patients. The secondary target of SARS-CoV-2" exact="infection" post="might be lymphocytes. Lymphocytopenia is a predominant feature of"/>
  <result pre="patients. The secondary target of SARS-CoV-2 infection might be lymphocytes." exact="Lymphocytopenia" post="is a predominant feature of COVID-19 patients in which"/>
  <result pre="feature of COVID-19 patients in which a large number of" exact="viral" post="RNAs within lymphocytes were detectedÂ [31], [33]. A recent"/>
  <result pre="be infected in human COVID-19 infectionÂ [91]. Fig. 5 Predicted" exact="viral" post="dynamics by model (3) under different scenarios. We use"/>
  <result pre="under different scenarios. We use the fitting to the LRT" exact="viral" post="load data of patient #2 inÂ [14], [54] as"/>
  <result pre="assumptions. (A) Model prediction with and without lymphocytes (i.e.Â the" exact="secondary" post="target of infection) and seroconversion. The adaptive immune response,"/>
  <result pre="day 5, 8, 10 and 12, respectively. Fig. 6 Predicted" exact="viral" post="rebound and persistence under different scenarios. We use the"/>
  <result pre="under different scenarios. We use the fitting to the URT" exact="viral" post="load data of patient #3 inÂ [14], [54] as"/>
  <result pre="patient #3 inÂ [14], [54] as an example to study" exact="viral" post="rebound and persistence with different assumptions. (A) Predicted viral"/>
  <result pre="study viral rebound and persistence with different assumptions. (A) Predicted" exact="viral" post="dynamics with different values of Ïƒ, the parameter determining"/>
  <result pre="cells increases as the adaptive immune response emerges. (B) Predicted" exact="viral" post="rebound and persistence assuming the adaptive immune response is"/>
  <result pre="South Korea treated with lopinavir/ritonavir. (A) Best fit to long-term" exact="viral" post="shedding in an adult rhesus macaqueÂ [52]; (B) Best"/>
  <result pre="lopinavir/ritonavir. (A) Best fit to long-term viral shedding in an" exact="adult" post="rhesus macaqueÂ [52]; (B) Best fit to the LRT"/>
  <result pre="adult rhesus macaqueÂ [52]; (B) Best fit to the LRT" exact="viral" post="load data of the Korean patient treated with lopinavir/ritonavirÂ"/>
  <result pre="data of the same patient in (B). Fig. 8 Predicted" exact="viral" post="dynamics under treatment. (A) The efficacy of antiviral drug"/>
  <result pre=". We performed simulation using the fit to the LRT" exact="viral" post="load data of patient #2 inÂ [14], [54] as"/>
  <result pre="be 104, 103, 102 and 10 cells mlâˆ’1Â dayâˆ’1, respectively." exact="Type I" post="IFN was used to treat MERS-CoV, SARS-CoV, and SARS-CoV-2"/>
  <result pre="SARS-CoV-2 infectionÂ [53], [92], [93]. The early treatment of MERS-CoV" exact="infection" post="protected mice from lethal infection but late induction could"/>
  <result pre="The early treatment of MERS-CoV infection protected mice from lethal" exact="infection" post="but late induction could result in serious pneumoniaÂ [92]."/>
  <result pre="drug efficacy needs to be close to 90% to suppress" exact="viral" post="replication effectively. However, intensification with interferon can more effectively"/>
  <result pre="intensification with interferon can more effectively reduce the duration of" exact="viral" post="plateau with a 60% efficacy of the antiviral drug."/>
  <result pre="SARS-CoV-2 and SARS-CoV shows that some changes, such as the" exact="absence of" post="open reading frame (ORF) 3b and a short truncation"/>
  <result pre="the absence of open reading frame (ORF) 3b and a" exact="short" post="truncation of ORF6 in SARS-CoV-2, can reduce the virusâ€™"/>
  <result pre="in SARS-CoV-2, can reduce the virusâ€™ capacity to interfere with" exact="type I" post="IFNÂ [53], [93]. ORF3b is a 154 amino acid"/>
  <result pre="truncation in its ORF6Â [53]. These alterations might make SARS-CoV-2" exact="infection" post="more sensitive to IFN. IFN was also administrated with"/>
  <result pre="IFN with and without other antiviral drugs to treat SARS-CoV-2" exact="infection" post="in humans. Table 2 Best fits of model (3)"/>
  <result pre="Table 2 Best fits of model (3) to the LRT" exact="viral" post="load data in patients from Germany. Patient Î² (ml/virus/day)"/>
  <result pre="Table 3 Best fits of model (3) to the URT" exact="viral" post="load data in patients from Germany. Patient Î² (ml/virus/day)"/>
  <result pre="Table 5 Best fits of model (3) to the rectal" exact="viral" post="load data of a non-human primate. Î² (ml/virus/day) p"/>
  <result pre="âˆ’5.835853 Table 6 Best fits of model (3) to the" exact="viral" post="data of a patient treated with lopinavir/ritonavir. Î² (ml/virus/day)"/>
  <result pre="coronavirus outbreak in Wuhan, ChinaInt. J. Infect. Dis.91202026426610.1016/j.ijid.2020.01.00931953166 2LuH.StrattonC.W.TangY.W.Outbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: The mystery and"/>
  <result pre="2019 novel coronavirus in Wuhan, ChinaLancet39510223202049750610.1016/S0140-6736(20)30183-531986264 4GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.Clinical characteristics of Coronavirus" exact="disease" post="2019 in ChinaNew Engl. J. Med.202010.1056/NEJMoa2002032 5ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A Novel Coronavirus"/>
  <result pre="ChinaNew Engl. J. Med.202010.1056/NEJMoa2002032 5ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A Novel Coronavirus from patients with" exact="Pneumonia" post="in China, 2019New Engl. J. Med.3828202072773310.1056/NEJMoa200101731978945 6ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.A familial cluster"/>
  <result pre="patients with Pneumonia in China, 2019New Engl. J. Med.3828202072773310.1056/NEJMoa200101731978945 6ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="in China, 2019New Engl. J. Med.3828202072773310.1056/NEJMoa200101731978945 6ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="of a family clusterLancet39510223202051452310.1016/s0140-6736(20)30154-931986261 7WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202010.1038/s41586-020-2008-310.1038/s41586-020-2008-3 8LiQ.GuanX.WuP.WangX.ZhouL.TongY.Early transmission dynamics in Wuhan, China,"/>
  <result pre="a family clusterLancet39510223202051452310.1016/s0140-6736(20)30154-931986261 7WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202010.1038/s41586-020-2008-310.1038/s41586-020-2008-3 8LiQ.GuanX.WuP.WangX.ZhouL.TongY.Early transmission dynamics in Wuhan, China, of"/>
  <result pre="in the United StatesNew Engl. J. Med.38210202092993610.1056/NEJMoa200119132004427 10Naming the coronavirus" exact="disease" post="(COVID-19) and the virus that causes it 2020. Available"/>
  <result pre="Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. 11KamelÂ BoulosM.N.GeraghtyE.M.Geographical tracking and mapping of coronavirus" exact="disease" post="COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and"/>
  <result pre="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. 11KamelÂ BoulosM.N.GeraghtyE.M.Geographical tracking and mapping of coronavirus disease COVID-19/severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events"/>
  <result pre="11KamelÂ BoulosM.N.GeraghtyE.M.Geographical tracking and mapping of coronavirus disease COVID-19/severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around"/>
  <result pre="BoulosM.N.GeraghtyE.M.Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) epidemic and associated events around the"/>
  <result pre="Novel Coronavirus in VietnamNew Engl. J. Med.3829202087287410.1056/NEJMc200127231991079 13RotheC.SchunkM.SothmannP.BretzelG.FroeschlG.WallrauchC.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyNew Engl. J. Med.38210202097097110.1056/NEJMc200146832003551"/>
  <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting wuhanEmerg Microbes Infect.91202022123610.1080/22221751.2020.171990231987001 18CuiJ.LiF.ShiZ.-L.Origin and evolution of"/>
  <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting wuhanEmerg Microbes Infect.91202022123610.1080/22221751.2020.171990231987001 18CuiJ.LiF.ShiZ.-L.Origin and evolution of"/>
  <result pre="21YinY.WunderinkR.G.MERS, SARS and other coronaviruses as causes of pneumoniaRespirology232201813013710.1111/resp.1319629052924 22ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="and its receptor CD26Nature5007461201322723110.1038/nature1232823831647 25QianZ.TravantyE.A.OkoL.EdeenK.BerglundA.WangJ.Innate immune response of human alveolar" exact="type II" post="cells infected with severe acute respiratory syndrome-coronavirusAm. J. Respir."/>
  <result pre="response of human alveolar type II cells infected with severe" exact="acute" post="respiratory syndrome-coronavirusAm. J. Respir. Cell. Mol. Biol.486201374274810.1165/rcmb.2012-0339OC23418343 26RajV.S.MouH.SmitsS.L.DekkersD.H.MÃ¼llerM.A.DijkmanR.Dipeptidyl peptidase"/>
  <result pre="of human alveolar type II cells infected with severe acute" exact="respiratory" post="syndrome-coronavirusAm. J. Respir. Cell. Mol. Biol.486201374274810.1165/rcmb.2012-0339OC23418343 26RajV.S.MouH.SmitsS.L.DekkersD.H.MÃ¼llerM.A.DijkmanR.Dipeptidyl peptidase 4"/>
  <result pre="for the emerging human coronavirus-EMCNature4957440201325125410.1038/nature1200523486063 27ScobeyT.YountB.L.SimsA.C.DonaldsonE.F.AgnihothramS.S.MenacheryV.D.Reverse genetics with a full-length" exact="infectious" post="cDNA of the Middle East respiratory syndrome coronavirusProc. Natl."/>
  <result pre="genetics with a full-length infectious cDNA of the Middle East" exact="respiratory" post="syndrome coronavirusProc. Natl. Acad. Sci. USA110402013161571616210.1073/pnas.131154211024043791 28RuanQ.YangK.WangW.JiangL.SongJ.Clinical predictors of"/>
  <result pre="with a full-length infectious cDNA of the Middle East respiratory" exact="syndrome" post="coronavirusProc. Natl. Acad. Sci. USA110402013161571616210.1073/pnas.131154211024043791 28RuanQ.YangK.WangW.JiangL.SongJ.Clinical predictors of mortality"/>
  <result pre="29YangX.YuY.XuJ.ShuH.XiaJ.LiuH.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir."/>
  <result pre="China: a single-centered, retrospective, observational studyLancet Respir. Med.202010.1016/s2213-2600(20)30079-5 30ChuH.ZhouJ.WongB.H.LiC.ChanJ.F.ChengZ.S.Middle east" exact="respiratory" post="syndrome coronavirus efficiently infects human primary T lymphocytes and"/>
  <result pre="a single-centered, retrospective, observational studyLancet Respir. Med.202010.1016/s2213-2600(20)30079-5 30ChuH.ZhouJ.WongB.H.LiC.ChanJ.F.ChengZ.S.Middle east respiratory" exact="syndrome" post="coronavirus efficiently infects human primary T lymphocytes and activates"/>
  <result pre="Respir. Med.202010.1016/s2213-2600(20)30079-5 30ChuH.ZhouJ.WongB.H.LiC.ChanJ.F.ChengZ.S.Middle east respiratory syndrome coronavirus efficiently infects human" exact="primary" post="T lymphocytes and activates the extrinsic and intrinsic apoptosis"/>
  <result pre="the extrinsic and intrinsic apoptosis pathwaysJ. Infect. Dis.2136201690491410.1093/infdis/jiv38026203058 31GuJ.GongE.ZhangB.ZhengJ.GaoZ.ZhongY.Multiple organ" exact="infection" post="and the pathogenesis of SARSJ. Exp. Med.2023200541542410.1084/jem.2005082816043521 32LiuW.J.ZhaoM.LiuK.XuK.WongG.TanW.T-cell immunity"/>
  <result pre="33WangH.MaoY.JuL.ZhangJ.LiuZ.ZhouX.Detection and monitoring of SARS coronavirus in the plasma and" exact="peripheral" post="blood lymphocytes of patients with severe acute respiratory syndromeClin."/>
  <result pre="the plasma and peripheral blood lymphocytes of patients with severe" exact="acute" post="respiratory syndromeClin. Chem.50720041237124010.1373/clinchem.2004.03123715229153 34PerlmanS.DandekarA.A.Immunopathogenesis of coronavirus infections: implications for"/>
  <result pre="plasma and peripheral blood lymphocytes of patients with severe acute" exact="respiratory" post="syndromeClin. Chem.50720041237124010.1373/clinchem.2004.03123715229153 34PerlmanS.DandekarA.A.Immunopathogenesis of coronavirus infections: implications for SARSNat."/>
  <result pre="membrane fusionCell. Mol. Immunol.202010.1038/s41423-020-0424-9 36XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.202010.1016/S2213-2600(20)30076-X 37ShiY.WangY.ShaoC.HuangJ.GanJ.HuangX.COVID-19 infection: the perspectives"/>
  <result pre="fusionCell. Mol. Immunol.202010.1038/s41423-020-0424-9 36XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.202010.1016/S2213-2600(20)30076-X 37ShiY.WangY.ShaoC.HuangJ.GanJ.HuangX.COVID-19 infection: the perspectives on"/>
  <result pre="on immune responsesCell Death Differ.202010.1038/s41418-020-0530-3 38PhuaJ.WengL.LingL.EgiM.LimC.M.DivatiaJ.V.Intensive care management of coronavirus" exact="disease" post="2019 (COVID-19): challenges and recommendationsLancet Respir. Med.202010.1016/s2213-2600(20)30161-2 39ThevarajanI.NguyenT.H.O.KoutsakosM.DruceJ.CalyL.SandtC.E.van.de.Breadth of"/>
  <result pre="a novel coronavirusInfect. Dis. Poverty9120202410.1186/s40249-020-00640-332111262 50KimJ.Y.KoJ.H.KimY.KimY.J.KimJ.M.ChungY.S.Viral load kinetics of SARS-CoV-2" exact="infection" post="in first two patients in KoreaJ. Korean Med. Sci.357202010.3346/jkms.2020.35.e86"/>
  <result pre="load of SARS-CoV-2 in clinical samplesLancet Infect. Dis.202010.1016/S1473-3099(20)30113-4 52MunsterV.J.FeldmannF.WilliamsonB.N.van DoremalenN.PÃ©rez-PÃ©rezL.SchulzJ.Respiratory" exact="disease" post="in rhesus macaques inoculated with SARS-CoV-2Nature202010.1038/s41586-020-2324-7 53LokugamageK.G.HageA.SchindewolfC.RajsbaumR.MenacheryV.D.SARS-CoV-2 is sensitive"/>
  <result pre="in rhesus macaques inoculated with SARS-CoV-2Nature202010.1038/s41586-020-2324-7 53LokugamageK.G.HageA.SchindewolfC.RajsbaumR.MenacheryV.D.SARS-CoV-2 is sensitive to" exact="type I" post="interferon pretreatment2020bioRxiv. 2020.03.07.982264. 10.1101/2020.03.07.982264 54BÃ¶hmerM.M.BuchholzU.CormanV.M.HochM.KatzK.MarosevicD.V.Investigation of a COVID-19 outbreak"/>
  <result pre="a COVID-19 outbreak in Germany resulting from a single travel-associated" exact="primary" post="case: a case seriesLancet Infect. Dis.202010.1016/s1473-3099(20)30314-5 55PerelsonA.S.RibeiroR.M.Modeling the within-host"/>
  <result pre="of the reninâ€&quot;angiotensin system be withdrawn in patients with COVID-19?Eur." exact="Heart" post="J.202010.1093/eurheartj/ehaa235 58BaigA.M.KhaleeqA.AliU.SyedaH.Evidence of the COVID-19 virus targeting the CNS:"/>
  <result pre="and proposed neurotropic mechanismsACS Chem Neurosci.202010.1021/acschemneuro.0c00122 59HaagmansB.L.KuikenT.MartinaB.E.FouchierR.A.RimmelzwaanG.F.van AmerongenG.Pegylated interferon-alpha protects" exact="type 1" post="pneumocytes against SARS coronavirus infection in macaquesNat Med.103200429029310.1038/nm100114981511 60XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological"/>
  <result pre="59HaagmansB.L.KuikenT.MartinaB.E.FouchierR.A.RimmelzwaanG.F.van AmerongenG.Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaquesNat Med.103200429029310.1038/nm100114981511 60XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with"/>
  <result pre="infection in macaquesNat Med.103200429029310.1038/nm100114981511 60XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med.84202042042210.1016/s2213-2600(20)30076-x32085846 61SweeneyR.M.McAuleyD.F.Acute respiratory distress syndromeLancet3881005820162416243010.1016/s0140-6736(16)00578-x27133972"/>
  <result pre="in macaquesNat Med.103200429029310.1038/nm100114981511 60XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med.84202042042210.1016/s2213-2600(20)30076-x32085846 61SweeneyR.M.McAuleyD.F.Acute respiratory distress syndromeLancet3881005820162416243010.1016/s0140-6736(16)00578-x27133972 62ManiconeA.M.Role"/>
  <result pre="COVID-19 associated with acute respiratory distress syndromeLancet Respir Med.84202042042210.1016/s2213-2600(20)30076-x32085846 61SweeneyR.M.McAuleyD.F.Acute" exact="respiratory" post="distress syndromeLancet3881005820162416243010.1016/s0140-6736(16)00578-x27133972 62ManiconeA.M.Role of the pulmonary epithelium and inflammatory"/>
  <result pre="syndromeLancet Respir Med.84202042042210.1016/s2213-2600(20)30076-x32085846 61SweeneyR.M.McAuleyD.F.Acute respiratory distress syndromeLancet3881005820162416243010.1016/s0140-6736(16)00578-x27133972 62ManiconeA.M.Role of the" exact="pulmonary" post="epithelium and inflammatory signals in acute lung injuryExpert. Rev."/>
  <result pre="syndromeLancet3881005820162416243010.1016/s0140-6736(16)00578-x27133972 62ManiconeA.M.Role of the pulmonary epithelium and inflammatory signals in" exact="acute" post="lung injuryExpert. Rev. Clin. Immunol.512009637510.1586/177666x.5.1.6319885383 63MasonR.J.Pathogenesis of COVID-19 from"/>
  <result pre="biology perspectiveEur. Respir. J.5542020200060710.1183/13993003.00607-2020 64MizumotoK.KagayaK.ZarebskiA.ChowellG.Estimating the asymptomatic proportion of coronavirus" exact="disease" post="2019 (COVID-19) cases on board the Diamond Princess cruise"/>
  <result pre="ship, Yokohama, Japan, 2020Euro Surveill.2510202010.2807/1560-7917.Es.2020.25.10.2000180 65GaoZ.XuY.SunC.WangX.GuoY.QiuS.A systematic review of asymptomatic" exact="infections" post="with COVID-19J. Microbiol. Immunol. Infect.202010.1016/j.jmii.2020.05.001 66Vukmanovic-StejicM.ZhangY.CookJ.E.FletcherJ.M.McQuaidA.MastersJ.E.Human CD4+ CD25hi Foxp3+"/>
  <result pre="T- and B-Lymphocyte Turnover in a natural host of simian" exact="immunodeficiency" post="virusJ. Virol.8232008108410.1128/JVI.02197-0718032490 68PawelekK.A.HuynhG.T.QuinlivanM.CullinaneA.RongL.PerelsonA.S.Modeling within-host dynamics of influenza virus infection"/>
  <result pre="of simian immunodeficiency virusJ. Virol.8232008108410.1128/JVI.02197-0718032490 68PawelekK.A.HuynhG.T.QuinlivanM.CullinaneA.RongL.PerelsonA.S.Modeling within-host dynamics of influenza" exact="virus infection" post="including immune responsesPLoS Comput. Biol.86201210.1371/journal.pcbi.1002588 69WangS.HottzP.SchechterM.RongL.Modeling the slow CD4+"/>
  <result pre="simian immunodeficiency virusJ. Virol.8232008108410.1128/JVI.02197-0718032490 68PawelekK.A.HuynhG.T.QuinlivanM.CullinaneA.RongL.PerelsonA.S.Modeling within-host dynamics of influenza virus" exact="infection" post="including immune responsesPLoS Comput. Biol.86201210.1371/journal.pcbi.1002588 69WangS.HottzP.SchechterM.RongL.Modeling the slow CD4+"/>
  <result pre="functions, and faultsBlood112520081557156910.1182/blood-2008-05-07815418725574 73GutcherI.BecherB.APC-Derived cytokines and T cell polarization in" exact="autoimmune" post="inflammationJ. Clin. Invest.117520071119112710.1172/JCI3172017476341 74OchsM.NyengaardJ.R.JungA.KnudsenL.VoigtM.WahlersT.The number of alveoli in the"/>
  <result pre="lungAm. J. Respir. Crit. Care Med.1691200412012410.1164/rccm.200308-1107OC14512270 75KidsHealth, Your Lungs &amp;amp;" exact="Respiratory" post="System. Available from: https://kidshealth.org/en/kids/lungs.html. 76CastranovaV.RabovskyJ.TuckerJ.H.MilesP.R.The alveolar type II epithelial"/>
  <result pre="Your Lungs &amp;amp; Respiratory System. Available from: https://kidshealth.org/en/kids/lungs.html. 76CastranovaV.RabovskyJ.TuckerJ.H.MilesP.R.The alveolar" exact="type II" post="epithelial cell: a multifunctional pneumocyteToxicol. Appl. Pharmacol.933198847248310.1016/0041-008x(88)90051-83285521 77BestK.GuedjJ.MadelainV.deÂ LamballerieX.LimS.-Y.OsunaC.E.Zika"/>
  <result pre="&amp;amp; Respiratory System. Available from: https://kidshealth.org/en/kids/lungs.html. 76CastranovaV.RabovskyJ.TuckerJ.H.MilesP.R.The alveolar type II" exact="epithelial" post="cell: a multifunctional pneumocyteToxicol. Appl. Pharmacol.933198847248310.1016/0041-008x(88)90051-83285521 77BestK.GuedjJ.MadelainV.deÂ LamballerieX.LimS.-Y.OsunaC.E.Zika plasma"/>
  <result pre="epithelial cell: a multifunctional pneumocyteToxicol. Appl. Pharmacol.933198847248310.1016/0041-008x(88)90051-83285521 77BestK.GuedjJ.MadelainV.deÂ LamballerieX.LimS.-Y.OsunaC.E.Zika plasma" exact="viral" post="dynamics in nonhuman primates provides insights into early infection"/>
  <result pre="plasma viral dynamics in nonhuman primates provides insights into early" exact="infection" post="and antiviral strategiesProc. Natl. Acad. Sci. USA1143320178847885210.1073/pnas.170401111428765371 78McElreathR.Statistical Rethinking:"/>
  <result pre="Business Decisions2019McGraw-Hill Education 80DuR.-H.LiangL.-R.YangC.-Q.WangW.CaoT.-Z.LiM.Predictors of mortality for patients with COVID-19" exact="pneumonia" post="caused by SARS-CoV-2: A prospective cohort studyEur. Respir. J.2020200052410.1183/13993003.00524-2020"/>
  <result pre="10.1101/2020.03.06.20031377 84TanL.KangX.ZhangB.ZhengS.LiuB.YuT.A special case of COVID-19 with long duration of" exact="viral" post="shedding for 49 days2020medRxiv. 2020.03.22.20040071. 10.1101/2020.03.22.20040071 85leilJian-yaG.Clinical characteristics of"/>
  <result pre="vitroCell Res.303202026927110.1038/s41422-020-0282-032020029 87ShamH.L.KempfD.J.MollaA.MarshK.C.KumarG.N.ChenC.M.ABT-378, a highly potent inhibitor of the human" exact="immunodeficiency" post="virus proteaseAntimicrob .Agents Chemother.4212199832183224Epub 1998/12/03. PubMed PMID: 9835517; PubMed"/>
  <result pre="immunodeficiency virus proteaseAntimicrob .Agents Chemother.4212199832183224Epub 1998/12/03. PubMed PMID: 9835517; PubMed" exact="Central" post="PMCID: PMCPMC1060259835517 88TchesnokovE.P.FengJ.Y.PorterD.P.GÃ¶tteM.Mechanism of inhibition of ebola virus RNA-dependent"/>
  <result pre="cleavage at two distinct sitesProc. Natl. Acad. Sci. USA1061420095871587610.1073/pnas.080952410619321428 90JaumeM.YipM.S.CheungC.Y.LeungH.L.LiP.H.KienF.Anti-severe" exact="acute" post="respiratory syndrome coronavirus spike antibodies trigger infection of human"/>
  <result pre="at two distinct sitesProc. Natl. Acad. Sci. USA1061420095871587610.1073/pnas.080952410619321428 90JaumeM.YipM.S.CheungC.Y.LeungH.L.LiP.H.KienF.Anti-severe acute" exact="respiratory" post="syndrome coronavirus spike antibodies trigger infection of human immune"/>
  <result pre="two distinct sitesProc. Natl. Acad. Sci. USA1061420095871587610.1073/pnas.080952410619321428 90JaumeM.YipM.S.CheungC.Y.LeungH.L.LiP.H.KienF.Anti-severe acute respiratory" exact="syndrome" post="coronavirus spike antibodies trigger infection of human immune cells"/>
  <result pre="Sci. USA1061420095871587610.1073/pnas.080952410619321428 90JaumeM.YipM.S.CheungC.Y.LeungH.L.LiP.H.KienF.Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger" exact="infection" post="of human immune cells via a pH- and cysteine"/>
  <result pre="92ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.IFN-I Response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ. Clin. Invest.130920193625363910.1172/jci126363 93ToturaA.L.BaricR.S.SARS Coronavirus pathogenesis: host innate immune"/>
  <result pre="Clin. Invest.130920193625363910.1172/jci126363 93ToturaA.L.BaricR.S.SARS Coronavirus pathogenesis: host innate immune responses and" exact="viral" post="antagonism of interferonCurr. Opin. Virol.23201226427510.1016/j.coviro.2012.04.00422572391 94Kopecky-BrombergS.A.MartÃ­nez-SobridoL.FriemanM.BaricR.A.PaleseP.Severe acute respiratory syndrome"/>
  <result pre="immune responses and viral antagonism of interferonCurr. Opin. Virol.23201226427510.1016/j.coviro.2012.04.00422572391 94Kopecky-BrombergS.A.MartÃ­nez-SobridoL.FriemanM.BaricR.A.PaleseP.Severe" exact="acute" post="respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF"/>
  <result pre="responses and viral antagonism of interferonCurr. Opin. Virol.23201226427510.1016/j.coviro.2012.04.00422572391 94Kopecky-BrombergS.A.MartÃ­nez-SobridoL.FriemanM.BaricR.A.PaleseP.Severe acute" exact="respiratory" post="syndrome coronavirus open reading frame (ORF) 3b, ORF 6,"/>
  <result pre="and viral antagonism of interferonCurr. Opin. Virol.23201226427510.1016/j.coviro.2012.04.00422572391 94Kopecky-BrombergS.A.MartÃ­nez-SobridoL.FriemanM.BaricR.A.PaleseP.Severe acute respiratory" exact="syndrome" post="coronavirus open reading frame (ORF) 3b, ORF 6, and"/>
  <result pre="6, and nucleocapsid proteins function as interferon antagonistsJ. Virol.812200754855710.1128/JVI.01782-0617108024 95FriemanM.YountB.HeiseM.Kopecky-BrombergS.A.PaleseP.BaricR.S.Severe" exact="acute" post="respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering"/>
  <result pre="and nucleocapsid proteins function as interferon antagonistsJ. Virol.812200754855710.1128/JVI.01782-0617108024 95FriemanM.YountB.HeiseM.Kopecky-BrombergS.A.PaleseP.BaricR.S.Severe acute" exact="respiratory" post="syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear"/>
  <result pre="nucleocapsid proteins function as interferon antagonistsJ. Virol.812200754855710.1128/JVI.01782-0617108024 95FriemanM.YountB.HeiseM.Kopecky-BrombergS.A.PaleseP.BaricR.S.Severe acute respiratory" exact="syndrome" post="coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import"/>
 </snippets>
</snippetsTree>
